Analyst Brian Cheng from J.P. Morgan maintained a Buy rating on Roivant Sciences and keeping the price target at $16.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brian Cheng’s rating is based on Roivant Sciences’ promising pipeline and strategic positioning in the biotech sector. The company has a diverse portfolio, including subsidiaries like Immunovant, Priovant, and Pulmovant, which provide multiple opportunities for success. Cheng highlights the upcoming pivotal readout of brepocitinib in dermatomyositis as a significant catalyst that could lead to approval and further diversify Roivant’s portfolio.
Cheng also notes that the current market valuation does not fully reflect the potential of Roivant’s portfolio. The company’s catalyst-rich calendar is expected to sustain investor interest, and the positive outlook for brepocitinib’s sales projections supports a favorable risk-reward profile. Cheng’s analysis incorporates a detailed valuation model, assigning specific values to key subsidiaries, which underpins the Buy rating with a price target of $16 by December 2025.
In another report released on September 3, Citi also initiated coverage with a Buy rating on the stock with a $16.00 price target.
Based on the recent corporate insider activity of 118 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ROIV in relation to earlier this year.